Introduction
============

The cell surface marker CD133 (prominin 1) has long been regarded as a classic signature of cancer stem cells (CSCs) in glioblastomas ([@b1-ol-0-0-5548],[@b2-ol-0-0-5548]). However, there has been controversy surrounding the existence of brain tumor-initiating cells lacking CD133 expression ([@b3-ol-0-0-5548]--[@b7-ol-0-0-5548]), as well as subpopulation heterogeneity in CD133^+^ cells ([@b8-ol-0-0-5548]). For convenience, CSCs are designated here as CD133^+^-expressing cells of glioblastomas. Despite conflicting views concerning their origin, evidence from previous studies, including our own previous study, has revealed that the endothelial progenitor cell (EPC) subpopulation in CSCs (CD34^+^/CD133^+^ cells) has angiogenic potential ([@b9-ol-0-0-5548]--[@b12-ol-0-0-5548]). Our previous study demonstrated that this proportion of the CD34^+^/CD133^+^ EPC subpopulation in CSCs varies among different tumor types, and that EPCs are not oncogenic ([@b9-ol-0-0-5548]). In fact, it is the non-EPC subpopulation in CSCs (CD34^−^/CD133^+^ cells) that has oncogenic potential ([@b9-ol-0-0-5548]). Therefore, it is of interest to evaluate the fractions of these cell subpopulations in CSCs from individual glioblastoma patients and to predict their oncogenic and angiogenic potential.

Glioblastoma is a highly vascularized tumor. Glioma contrast enhancement detected using magnetic resonance imaging (MRI) may be due to angiogenesis, tumor cell proliferation and blood-brain barrier disruption. Numerous studies have investigated the correlation between characteristics identified by tumor imaging and the molecular signatures of gliomas ([@b13-ol-0-0-5548]--[@b15-ol-0-0-5548]). Thus, the finding of significant associations between molecular characteristics and specific MRI tumor features may lead to the establishment of a non-invasive method of predicting molecular signatures that aids in selecting treatment options, or even in predicting the prognosis of individual patients.

In this study, we examined the associations between subpopulation fractions of CSCs and their MRI characteristics. First, we tested whether contrast enhancement is associated with EPC fractions in glioblastoma CSCs and then investigated whether angiogenesis is influenced by EPC fractions. We observed that non-EPC fractions in CSCs are associated with the proliferation and contrast enhancement phenotype in glioblastomas.

Materials and methods
=====================

### Study population

Ten patients with newly diagnosed glioblastoma were selected from the Department of Neurosurgery database (Seoul National University Hospital, Korea), according to the radiographic characteristics. Based on preoperative MRIs demonstrating contrast enhancement, necrosis and infiltrative patterns, patients were classified into two groups: the enhancement/necrosis group (E/N, n=5) and the non-enhancement/infiltration group (NE/I, n=5; [Fig. 1](#f1-ol-0-0-5548){ref-type="fig"}). For the E/N group, patients were selected if they had the following MRI characteristics: a contrast-enhancing volume exceeding 50% of the entire tumor volume; the presence of necrosis; and minimal-high T2 signal intensity areas around the contrast-enhancing and necrotic portions of the tumor. For the NE/I group, patients were selected if they had the following MRI characteristics: the absence of, or only patchy (\<5% of the entire tumor volume) enhancement in the tumor; no evidence of necrosis; and an ill-defined margin of high T2 signal intensity without the classic appearance of vasogenic edema. The histological diagnosis of glioblastoma was confirmed in all cases following surgery. The general characteristics of the patients and molecular characteristics of their tumors are summarized in [Table I](#tI-ol-0-0-5548){ref-type="table"}. This study was approved by the Institutional Review Board of Seoul National University Hospital, and patient consent was obtained.

### Tissue samples

Tissue samples were obtained intra-operatively. A number of tumor samples were snap-frozen in liquid nitrogen in the operating room and stored at −80°C until subsequent use for fluorescence-activated cell sorting (FACS) analyses. The remaining tissue samples were fixed with formalin and embedded in paraffin (FFPE). Using the FFPE samples, a tissue microarray was built for immunohistochemistry (IHC) studies. Representative paraffin blocks were selected and mounted on slides for hematoxylin and eosin (H&E) staining. Cores from representative areas of each tumor were marked on an H&E-stained tissue section and an original donor block. Three 2-mm-diameter tissue cores were extracted from the marked area of each donor block. A 4-µm-thick section was cut from each array block.

### Tissue FACS

Tissue FACS was performed as previously described, with a few modifications ([@b16-ol-0-0-5548]). For the dissociation of frozen tumor tissues, the tissues were washed twice with sterile phosphate-buffered saline (PBS) and minced using a steel blade. The tissues were enzymatically digested by incubation with an enzyme cocktail (100 U/ml collagenase, 0.001 U/ml DNase1 and 2.4 U/ml dispase) for 1 h at 37°C and then filtered through a Falcon^®^ 40 µm cell strainer (cat. no. 352340; Corning Life Sciences, Corning, NY, USA) to remove any clumps or tissue debris. Red blood cells in the samples were removed by incubation with Buffer EL (cat. no. 19075, Qiagen, Valencia, CA, USA). Cells were re-suspended in Dulbecco\'s modified Eagle\'s medium (DMEM; cat. no. LM001-05; Welgene Inc., Seoul, Korea), with 10% Gibco^®^ fetal bovine serum (FBS; cat. no. 12483-020; Invitrogen Life Technologies, Carlsbad, CA, USA) and 1% Gibco Antibiotic-Antimycotic (cat. no. 15240-060; Invitrogen Life Technologies), and then incubated overnight at 37°C in humidified atmosphere containing 5% carbon dioxide.

Specimens were washed twice with FACS buffer (PBS containing 2% Gibco FBS (cat. no. 12483-020; Invitrogen Life Technologies) and stained with pre-conjugated monoclonal antibodies with allophycocyanin (APC)-conjugated CD133/2 antibody (cat. no. 130-090-854; 1:10; clone 293C3; Miltenyi Biotec, Bergisch Gladbach, Germany) or fluorescein isothiocyanate (FITC)-conjugated CD34 antibody (cat. no. 130-081-001; 1:10; clone AC136; Miltenyi Biotec) for 30 min at 4°C, and then washed twice with FACS buffer. Flow cytometry analysis was performed on an LSRII (BD Biosciences, San Jose, CA, USA), and forward light scatter and side scatter were recorded using 100,000 cells. Data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA).

### Immunohistochemistry

IHC was performed as previously described, with a few modifications ([@b17-ol-0-0-5548],[@b18-ol-0-0-5548]). Briefly, tissue microarrays of human glioblastoma samples were deparaffinized and rehydrated, and then endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 5 min. Following incubation with a universal blocking buffer (2% FBS in PBS) for 30 min to suppress nonspecific binding, the array slides were coated with primary antibodies \[rabbit anti-CD133 (PROM1), 1:100, Abnova, Taipei, Taiwan; goat anti-CD45 (N-19), 1:100, Santa Cruz Biotechnology, Inc., Dallas, TX, USA; rabbit anti-vascular endothelial growth factor receptor 1 (VEGFR1; Y103), 1:25, Abcam, Cambridge, MA, USA; rabbit anti-VEGFR2 (EPRER16Y), 1:50, Abcam; rat anti-Notch1 (bTAN 20), 1:100, Abcam; mouse anti-integrin β4 (58XB4), 1:100, Abcam; and rat anti-CD34 (QBEnd 10), 1:100, Dako, Glostrup, Denmark\] for 1 h at room temperature. The detection system used was a Universal Dako Labelled Streptavidin-Biotin2 system, Horseradish Peroxidase (LSAB2 system, HRP) for CD133, VEGFR1, VEGFR2 and integrin β4, and a VECTASTAIN Elite ABC kit for CD45, Notch1 and CD34.

All slides, except for CD34 \[which used 3-amino-9-ethylcarbazole (product no. K346430; Dako) for 10 min\], were developed using 3,3′-diaminobenzidine (product no. S196730; Dako) for 10 min, and each slide was counterstained with Mayer\'s hematoxylin for 15 sec. Staining intensity was quantified using the Aperio ImageScope (v12.0; Aperio Technologies, Vista, CA, USA) positive pixel count algorithm in 10 random fields (250×250 µm) from each slide ([@b19-ol-0-0-5548]). IHC staining results were semiquantitatively graded as follows: no staining detected (0, no positive tumor cells), faint staining (1+, \<10% positive tumor cells), moderate staining (2+, 10--50% positive tumor cells), and strong staining (3+, \>50% positive tumor cells). In the case of the proliferation index assessed using antibody Ki-67, positive staining was defined as 2+ or 3+ based on the percentage of tumor cells demonstrating immunoreactivity.

Microvessel density (MVD) was assessed as described previously ([@b20-ol-0-0-5548]). Briefly, the areas of highest neovascularization were selected, and single, or clusters of, endothelial cells that were positive for CD31 or CD34 were counted. A minimum of five histological fields were assessed to estimate the mean MVD for each case.

### Imaging

Follow-up MRI scans of all patients were carried out using a 3-Tesla MR imaging scanner (Signa Excite, GE Medical Systems, Milwaukee, WI, USA; and Verio, Siemens Medical Solutions, Erlangen, Germany) with an eight-channel head coil. The imaging protocol included spin-echo (SE) T1-weighted images (T1WIs), fast SE (FSE) T2-weighted images (T2WIs), fluid-attenuated inversion recovery (FLAIR) images, echo-planar diffusion-weighted images, susceptibility-weighted images (SWIs), dynamic susceptibility contrast-enhanced perfusion-weighted images (DSC PWIs) with gadobutrol (Gadovist, Bayer Schering Pharma, Berlin, Germany), and subsequent contrast-enhanced (CE) SE T1WIs. The MRI parameters were as follows: 558--650/8--20 ms/70--90°/384×192--212 \[repetition time (TR)/echo time (TE)/flip angle (FA)/matrix\] for SE T1WIs; 4500--5160/91--106.3 ms/90--130°/448--640×220 for FSE T2WIs; 9000--9900/97--162.9 ms/90--130°/199--220×220 for FLAIR images; and 28/20 ms/15°/448×255 for SWIs. The other parameters included section thickness of 5 mm with a 1-mm gap and field of view (FOV) of 240×240 mm.

DSC PWI was performed with a single-shot gradient-echo echo-planar imaging sequence during intravenous injection of the contrast agent. The imaging parameters of DSC PWI were as follows: TR/TE, 1500/30--40 ms; FA, 35--90°; FOV, 240×240 mm; 15--20 sections; matrix, 128×128; section thickness, 5 mm; intersection gap, 1 mm; and voxel resolution, 1.86×1.86×5 mm. For each section, 60 images were obtained at intervals equal to the repetition time. After 4--5 time points, a bolus of gadobutrol, at a dose of 0.1 mmol/kg of body weight and a rate of 4 ml/second, was injected with a MR-compatible power injector (Spectris; Medrad Inc., Pittsburgh, PA, USA). The bolus of the contrast material was followed by a 30-ml bolus of saline, which was administered at the same injection rate.

### Quantitative analysis of imaging values

The MRI data for the conventional MR images, the apparent diffusion coefficient (ADC) maps, and the DSC PWIs were digitally transferred from the picture archiving and communication system workstation to a personal computer for further analyses. Relative cerebral blood volumes (rCBVs) were obtained using a dedicated software package (nordicICE; NordicImagingLab, Bergen, Norway), with an established tracer kinetic model applied to first-pass data. First, realignment was performed to minimize patient motion during the dynamic scans. Gamma-variate function, which is an approximation of the first-pass response as it would appear in the absence of recirculation, was used to fit the 1/T2\* (1/T2 + γΔBinhom, where γ is the gyromagnetic ratio) curves to reduce the effects of recirculation. To reduce contrast agent leakage effects, the dynamic curves were mathematically corrected ([@b21-ol-0-0-5548]). Following elimination of recirculation and of leakage of the contrast agent, the rCBV was computed by means of numeric integration of the curve. To minimize variances in the rCBV value in an individual patient, the pixel-based rCBV maps were normalized by dividing every rCBV value in a specific section by the rCBV value in the unaffected white matter, as defined by a neuroradiologist ([@b22-ol-0-0-5548]). Co-registrations between the CE T1WIs and the normalized CBV (nCBV) maps, and between the CE T1WIs and the ADC maps, were performed, based on geometric information stored in their respective data sets, using the dedicated software package nordicICE ([@b22-ol-0-0-5548]). The differences in slice thickness between the images were corrected automatically by the reslicing and co-registration method, which was based on the underlying and structural images. The nCBV and ADC maps were displayed as color overlays on the CE T1WIs.

Using histograms of the nCBV and ADC maps, we obtained the mean, mode, skewness and kurtosis for comparison.

### Statistical analysis

All statistical analyses were carried out using IBM SPSS statistical software version 21 (IBM SPSS, Armonk, NY, USA). The Mann-Whitney U test was used to compare two groups of observations, and the Kendall tau to calculate the correlation coefficient. All analyses were two-sided, and P\<0.1 was considered to indicate a statistically significant difference.

Results
=======

### Higher CD34^+^ cell fraction in CD133^+^ cells in NE/I glioblastomas

Tumor cell populations expressing CD133 and CD34 were measured by tissue FACS. The subpopulation fraction results for individual cases are presented in [Table II](#tII-ol-0-0-5548){ref-type="table"}. The median fraction of CD133^+^ cells represented 0.16% (range, 0.05--5.95%) of the total tumor cell population per case. The CD133^+^ cell fraction was higher in the E/N group than in the NE/I group ([Fig. 2A](#f2-ol-0-0-5548){ref-type="fig"}; median 0.62% vs. 0.07%, respectively; P=0.076). However, there was no difference in the CD34^+^ cell fraction between the two groups ([Fig. 2B](#f2-ol-0-0-5548){ref-type="fig"}; median 4.04% vs. 3.41%, respectively; P=0.754). The median fraction of CD34^+^ cells in the total tumor cell population per case was 3.41% (range, 1.08--16.78%). However, the percentage expressing CD34^+^ in the CD133^+^ cell fraction (EPC fraction in CSCs, CD34^+^/CD133^+^) was significantly higher in the NE/I group than the E/N group ([Fig. 2C](#f2-ol-0-0-5548){ref-type="fig"}; 25.58% vs. 14.37%, respectively; P=0.009). On the other hand, the percentage expressing CD34^−^ cells in the CD133^+^ cell fraction (non-EPC fraction in CSCs, CD34^−^/CD133^+^) was significantly higher in the E/N group than the NE/I group (87.90% vs. 62.63%, respectively; P=0.008).

### Angiogenesis is phenotype-independent in glioblastomas

Double-staining IHC for CD133 and CD34 identified the perivascular localization of the CD34^+^/CD133^+^ cells ([Fig. 3A](#f3-ol-0-0-5548){ref-type="fig"}). However, there was no statistical difference in MVD between the E/N and NE/I groups ([Fig. 3B](#f3-ol-0-0-5548){ref-type="fig"}). There was also no difference in protein expression related to angiogenesis between the two groups ([Table III](#tIII-ol-0-0-5548){ref-type="table"}).

Histogram analysis for perfusion MRI is summarized in [Table IV](#tIV-ol-0-0-5548){ref-type="table"}. When comparing the histogram parameters between the E/N and NE/I groups, only the skewness of nCBV was significantly different (P=0.048). There were no differences in other perfusion MRI parameters between the two groups.

### Higher proliferative potential in E/N glioblastomas correlates with CD34^−^/CD133^+^ cell fraction

Proliferation index measurement, using Ki-67 IHC, revealed a significant increase in the E/N group, compared with the NE/I group ([Fig. 4A](#f4-ol-0-0-5548){ref-type="fig"}; 18.5±6.3% vs. 8.4±6.6%; P=0.004). As the E/N group had a larger CD34^−^/CD133^+^ cell fraction than the NE/I group, we examined the correlation between CD34^−^/CD133^+^ cell fractions and Ki-67 in whole-study samples. A positive correlation was observed between CD34^−^/CD133^+^ cell fractions and Ki-67 ([Fig. 4B](#f4-ol-0-0-5548){ref-type="fig"}; *R*=0.467, P=0.060). This result indicates that a larger CD34^−^/CD133^+^ cell fraction correlates with a greater cellular proliferation and is associated with the E/N radiographic phenotype.

Discussion
==========

We have previously demonstrated that there is a distinct subpopulation of CD133^+^ cells in human brain tumors, with characteristics of EPCs (CD34^+^/CD133^+^) ([@b9-ol-0-0-5548]). The functional role of EPCs in oncogenesis has been identified as that of increased angiogenic potential, which is an essential element for tumor progression ([@b9-ol-0-0-5548]). EPCs are known to be recruited to sites of neovascularization from the bone marrow, or to be transdifferentiated from CSCs ([@b12-ol-0-0-5548],[@b23-ol-0-0-5548]--[@b26-ol-0-0-5548]). In addition, we observed various EPC fractions in CSCs among different cancer types ([@b9-ol-0-0-5548]). This led to the speculation of a possible correlation between EPC fractions and phenotypic characteristics associated with angiogenesis in specific tumors. Glioblastoma is the ideal tissue material to test this hypothesis, as it harbors heterogeneous imaging characteristics, thus implying a diverse degree of angiogenesis, necrosis and proliferation. Furthermore, it has also been studied extensively using advanced imaging techniques, thus providing us with sufficient cumulative knowledge for the imaging characteristics to be interpreted. Therefore, we defined two phenotypically distinct groups of glioblastoma, based on their MRI characteristics, which we then used to test the hypothesis. We consider that the E/N group is representative of angiogenesis-prone cases while the NE/I group represents cases with lower angiogenic potential.

Against our expectations, there was no evidence of differences in angiogenic activity between the two groups assessed by MVD. Moreover, the EPC fraction (CD34^+^/CD133^+^) in CSCs was higher in the NE/I group whereas the CD34^−^/CD133^+^ cell fraction in the CD133^+^ cell population was significantly higher in the E/N group, compared with the NE/I group. This implies that angiogenic potential is not a major factor associated with radiographic phenotypic changes. There were also no differences in the perfusion MRI parameters, thus supporting the microscopic IHC evidence. This is in line with the findings of a previous study on glioblastoma, which revealed that there was histopathologically no difference in overall and simple vascular hyperplasia between samples from T1 contrast enhancement areas and samples from non-contrast areas ([@b27-ol-0-0-5548]). This study further demonstrated that delicate microvascular hyperplasia is more frequently observed in specimens from non-enhancement areas ([@b27-ol-0-0-5548]). Another previous study on the use of anti-angiogenic therapy for glioblastoma revealed that the significant reduction in contrast enhancement following anti-angiogenic treatment was not due to the decrease in MVD ([@b28-ol-0-0-5548]). The authors concluded that contrast enhancement does not accurately reflect vascular density ([@b28-ol-0-0-5548]). However, there are still conflicting views on the role of perfusion MRI for predicting MVD ([@b29-ol-0-0-5548]).

In our previous study, we confirmed that the CD34^−^/CD133^+^ subpopulation comprised the oncogenic cells that led to tumors *in vivo* ([@b9-ol-0-0-5548]). In the same study, we also revealed the CD34^−^/CD133^+^ cell fraction to be the major component for proliferation in tumor models ([@b9-ol-0-0-5548]). Results from the present study indicate that the CD34^−^/CD133^+^ fraction in the CD133^+^ cell population is higher in the E/N group compared with the NE/I group, and this correlated with the proliferation index. Therefore, this finding provides further support for the proliferative potential of the CD34^−^/CD133^+^ cell fraction in human glioblastoma samples. Moreover, we established an association between this subpopulation of CSCs and the radiographic characteristics of the tumors. Studies investigating MRI characteristics in the early phase of glioblastoma evolution have reported that ill-defined hyperintense areas on T2WIs without contrast enhancement represent the incipient stage of cancer ([@b30-ol-0-0-5548],[@b31-ol-0-0-5548]). Furthermore, a higher proliferative index in contrast-enhanced areas was documented by another research group ([@b27-ol-0-0-5548]).

The EPC fraction in CSCs was increased in glioblastomas without contrast enhancement on MRI. However, angiogenesis was not a major factor influencing radiographic characteristics. Our study suggests that the non-EPC fractions in CSCs are associated with oncogenic proliferation and are responsible for radiographic changes in glioblastomas. Therefore, as a surrogate marker of proliferation potential, the simple non-invasive assessment method of contrast enhancement lesions in glioblastoma could be used to estimate CSC subpopulations or to guide in the selection of therapeutic agents targeting CSCs. The limitation of this study is the lax statistical standard, and the small number of samples, which prohibits parametric tests between groups. Larger study samples are required to validate the results in the future.

Simple non-invasive assessment of contrast enhancement lesions for glioblastoma may be utilized to provide a biomarker for estimating the presence of subpopulations of CSCs.
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![T1 contrast-enhanced magnetic resonance image characteristics of the study population. Ten newly diagnosed glioblastoma patients were classified into the enhancement/necrosis (E/N, n=5) or non-enhancement/infiltration (NE/I, n=5) group based on contrast enhancement, necrosis and infiltrative pattern.](ol-13-03-1175-g00){#f1-ol-0-0-5548}

![Fractions of cells expressing CD133 and CD34 in tumor tissue assessed by fluorescence-activated cell sorting. (A) A higher CD133^+^ cell fraction was detected in the enhancement/necrosis (E/N) group than in the non-enhancement/infiltration (NE/I) group (median 0.62% vs. 0.07%, P=0.076). (B) No statistically significant differences were detected in the CD34^+^ cell fraction between the E/N group and NE/I group (median 4.04% vs. 3.41%, P=0.754). (C) A significantly higher percentage of CD34^+^/CD133^+^ cells was detected in the NE/I group than the E/N group (25.58% vs. 14.37%, P=0.009). \*P\<0.01. × represents an outlying data point.](ol-13-03-1175-g01){#f2-ol-0-0-5548}

![(A) Double immunohistochemical staining of CD133 (brown) and CD34 (red) protein expression in glioblastoma tissue. Note the perivascular localization of CD133^+^ and CD34^+^ cells. (B) Microvascular density indicates no statistical differences in angiogenesis features between the enhancement/necrosis (E/N) group and the non-enhancement/infiltration (NE/I) group. The blood vessels were immunohistochemically stained with anti-CD31 antibody. × represents an outlying data point](ol-13-03-1175-g02){#f3-ol-0-0-5548}

![Detection of proliferating cells in the glioblastomas. (A) A significantly higher proliferation index measured by Ki-67 was present in the enhancement/necrosis (E/N) group compared with the non-enhancement/infiltration (NE/I) group (18.5±6.3% vs. 8.4±6.6%, P=0.004). (B) Ki-67 was positively correlated with the CD34^−^/CD133^+^ fraction in glioblastoma tissues (R=0.467, P=0.060).](ol-13-03-1175-g03){#f4-ol-0-0-5548}

###### 

Baseline information of the study populations.

  A, Enhancement/necrosis group                                                                                                                             
  --------------------------------------- ------------ --------------------- ---------------------------------- --------------------------- --------------- --------------------
  1                                       F/68         GTR                   GBM (giant cell)                   Unmethylated                Wild-type       No
  2                                       M/59         GTR                   GBM (gemistocytic astrocytes)      Methylated                  Wild-type       No
  3                                       M/45         GTR                   GBM                                Methylated                  Wild-type       Yes
  4                                       F/67         NTR                   GBM (small cell)                   Methylated                  Wild-type       No
  5                                       F/34         STR                   GBM (oligodendroglial component)   Methylated                  Mutation        No
                                                                                                                                                            
  B, Non-enhancement/infiltration group                                                                                                                     
                                                                                                                                                            
  Case                                    Gender/age   Extent of resection   Pathology                          MGMT promoter methylation   IDH1 mutation   EGFR amplification
                                                                                                                                                            
  6                                       F/64         STR                   GBM (small cell)                   Methylated                  Wild-type       Yes
  7                                       M/43         NTR                   GBM (gemistocytic astrocytes)      Methylated                  Wild-type       No
  8                                       F/36         STR                   GBM (oligodendroglial component)   Methylated                  Mutation        No
  9                                       M/42         GTR                   GBM (oligodendroglial component)   Methylated                  Mutation        No
  10                                      M/46         GTR                   GBM                                Unmethylated                Wild-type       No

MGMT, O6-methylguanine-DNA methyltransferase; IDH1, isocitrate dehydrogenase 1; EGFR, epidermal growth factor receptor; GTR, gross total resection; NTR, near total resection; STR, subtotal resection; GBM, glioblastoma.

###### 

Distribution of tumor cell subpopulations expressing CD133 and CD34 in individual cases.

  A, Enhancement/necrosis group                                                                                                           
  --------------------------------------- ------------ -------------------- ------------------- ------------- ------------- ------------- -------------
  1                                       F/68         0.09                   1.40                1.12        98.88           0.95        99.05
  2                                       M/59         0.62                   7.36              12.32         87.68           7.17        92.83
  3                                       M/45         0.16                 16.78               14.37         85.63         12.25         87.75
  4                                       F/67         3.76                   4.04              16.04         83.96           4.10        95.90
  5                                       F/34         5.95                   1.08              16.67         83.33           0.89        99.11
                                                                                                                                          
  B, Non-enhancement/infiltration group                                                                                                   
                                                                                                                                          
                                                                                                CD133^+^      CD133^−^                    
                                                                                                                                          
  Case                                    Gender/age   Total CD133^+^ (%)   Total CD34^+^ (%)   CD34^+^ (%)   CD34^−^ (%)   CD34^+^ (%)   CD34^−^ (%)
                                                                                                                                          
  6                                       F/64         0.28                   8.82              22.00         78.00           9.07        90.93
  7                                       M/43         0.12                   1.38              22.06         77.94           1.19        98.81
  8                                       F/36         0.10                   1.85              25.58         74.42           1.63        98.37
  9                                       M/42         0.05                   3.41              35.00         65.00           3.29        96.71
  10                                      M/46         0.07                   2.27              82.22         17.78           2.10        97.90

###### 

Angiogenesis-related protein expression.

  Gene          Enhancement/necrosis group (%)   Non-enhancement/infiltration group (%)
  ------------- -------------------------------- ----------------------------------------
  CD45          2.2±1.7                          1.8±1.4
  VEGFR1        3.8±1.3                          4.5±3.4
  VEGFR2        3.3±3.1                          2.7±1.3
  Notch1        0.2±0.1                          0.3±0.4
  Integrin β4   1.2±1.6                          1.1±0.6

The immunohistochemical result of the percentage of positively stained cells in each phenotype group is expressed as the mean ± standard deviation. VEGFR, vascular endothelial growth factor receptor.

###### 

Normalized cerebral blood volume histogram parameters of each phenotype group.

  Gene       Enhancement/necrosis group (%)   Non-enhancement/infiltration group (%)   P-value
  ---------- -------------------------------- ---------------------------------------- ---------
  Mean       2.4±0.9                          2.0±0.8                                  0.535
  Mode       1.8±0.9                          2.8±0.7                                  0.921
  Kurtosis   2.8±1.3                          1.9±1.4                                  0.365
  Skewness   1.5±0.4                          1.0±0.4                                  0.048

Data are presented as means ± standard deviations.
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